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might be involved in high affinity transport of endoge- At the canalicular plasma membrane monoquaternary
drugs (for example, N-methyl-quinidine, N-methyl-qui-nous compounds in selected tissues in addition to their
nine) are transported in a stereospecific manner by ratrole in overall amphipathic drug clearance by the liver
Mdr1b and human MDR1, but not by Mdr2 [12].and other drug eliminating organs. Since the Oatps/
OATPs can remove amphipathic drugs from their albu-
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at the level of intestine, liver and kidney. On the otherThe last session was opened by Martin Fromm (Stutt-
hand, the antibiotic rifampicin enhances P-glycoproteingart, Germany), who talked about “ABC transporters and
(P-gp) expression and causes reduced plasma concentra-drug disposition.” Clinically important are, for example,
tions of P-gp substrates. In addition, a widespread C3435Tdrug-drug interactions such as the enhancement of blood
mutation of P-gp has been shown to be associated withconcentrations of the heart glycoside digoxin during con-
low level P-gp expression in gut and higher bioavailabilitycomitant treatment with the anti-arrhythmic drug quinidine
of digoxin in Caucasians [2].[1]. The underlying mechanism is inhibition of P-glycopro-
tein mediated digoxin transport, which occurs most likely Alfred Schinkel (Amsterdam, The Netherlands)
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stressed the importance of “In vivo P-gp inhibition to cholic acid modestly up-regulates via PXR Mrp2; in addi-
tion Mrp 4 is strongly up-regulated via PXR and theimprove the pharmacological behavior of HIV-protease
phenobarbital-sensitive nuclear factor CAR as well. Sinceinhibitors” such as of saquinavir and ritonavir. He showed
Mrp4 is present in the basolateral membrane of hepato-that combined application of ritonavir with saquinavir
cytes as well as in cholangiocytes, this ABC-carrier estab-increased blood levels of saquinavir by retarding its elim-
lishes a detoxification pathway under high bile salt load-ination, probably primarily by inhibition of its metabo-
ing, for example, during cholestasis [4].lism by the P450 protein Cyp 3A4. If an inhibitor of P-
gp was given in addition, blood and brain levels increased
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CYP3A11, CYP2B10 and Mrp4. This points to an impor-
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